ZA200002488B - Therapeutic formulation for administering tolterodine with controlled release. - Google Patents
Therapeutic formulation for administering tolterodine with controlled release.Info
- Publication number
- ZA200002488B ZA200002488B ZA200002488A ZA200002488A ZA200002488B ZA 200002488 B ZA200002488 B ZA 200002488B ZA 200002488 A ZA200002488 A ZA 200002488A ZA 200002488 A ZA200002488 A ZA 200002488A ZA 200002488 B ZA200002488 B ZA 200002488B
- Authority
- ZA
- South Africa
- Prior art keywords
- controlled release
- therapeutic formulation
- tolterodine
- formulations
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802864A SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200002488B true ZA200002488B (en) | 2001-05-16 |
Family
ID=20412370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200002488A ZA200002488B (en) | 1998-08-27 | 2000-05-19 | Therapeutic formulation for administering tolterodine with controlled release. |
Country Status (13)
Country | Link |
---|---|
US (2) | US6517864B1 (xx) |
EP (1) | EP1105111B1 (xx) |
JP (1) | JP2002523446A (xx) |
AT (1) | ATE405254T1 (xx) |
AU (1) | AU758399B2 (xx) |
CA (1) | CA2341063C (xx) |
DE (1) | DE69939382D1 (xx) |
ES (2) | ES2310942T3 (xx) |
NZ (1) | NZ509928A (xx) |
SE (1) | SE9802864D0 (xx) |
TW (1) | TWI253349B (xx) |
WO (1) | WO2000012070A1 (xx) |
ZA (1) | ZA200002488B (xx) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000515525A (ja) * | 1996-07-19 | 2000-11-21 | アベーグ,グンナー | 尿と胃腸の疾患の治療におけるs(―)―トルテロジン |
EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
SE9802864D0 (sv) * | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
EP1031347B1 (en) | 1999-01-27 | 2002-04-17 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
PT1031346E (pt) | 1999-01-27 | 2002-09-30 | Idea Ag | Vacinacao nao invasiva atraves da pele |
DE19922662C1 (de) * | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
MXPA02000053A (es) * | 1999-07-05 | 2003-07-21 | Idea Ag | Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables. |
DE19932651A1 (de) * | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
PL370889A1 (en) * | 2001-12-20 | 2005-05-30 | Femmepharma, Inc. | Vaginal delivery of drugs |
WO2004060322A2 (en) * | 2003-01-02 | 2004-07-22 | Femmepharma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
US9173836B2 (en) | 2003-01-02 | 2015-11-03 | FemmeParma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
US20040191345A1 (en) * | 2003-03-26 | 2004-09-30 | Fredrik Nicklasson | New formulations and use thereof |
DE10315917A1 (de) | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
US20060188554A1 (en) * | 2003-08-04 | 2006-08-24 | Katashi Nakashima | Transdermal absorption preparation |
US7537590B2 (en) * | 2004-07-30 | 2009-05-26 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
US20110071204A1 (en) * | 2005-02-03 | 2011-03-24 | Kyorin Pharmaceutical Co., Ltd. | Percutaneous absorption preparation |
WO2007046102A2 (en) | 2005-10-19 | 2007-04-26 | Menni Menashe Zinger | Methods for the treatment of hyperhidrosis |
AU2012261753B2 (en) * | 2006-04-13 | 2015-03-05 | Teva Pharmaceuticals International Gmbh | Transdermal methods and systems for the delivery of anti-migraine compounds |
CN101472644B (zh) * | 2006-04-13 | 2014-04-23 | 纽帕特公司 | 递送抗偏头痛化合物的透皮方法和系统 |
EP2019679B1 (en) | 2006-05-23 | 2018-06-20 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
WO2008083158A2 (en) * | 2006-12-26 | 2008-07-10 | Femmepharma Holding Company, Inc. | Topical administration of danazol |
US20080193766A1 (en) * | 2007-02-13 | 2008-08-14 | Northern Nanotechnologies | Control of Transport to and from Nanoparticle Surfaces |
RU2492175C2 (ru) | 2007-04-02 | 2013-09-10 | Теракос, Инк. | Бензиловые производные гликозидов и способы их применения |
US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
LT2187742T (lt) | 2007-08-23 | 2018-01-10 | Theracos Sub, Llc | (2s,3r,4r,5s,6r)-2-(4-chlor-3-benzilfenil)-6-(hidroksimetil)tetrahidro-2h-piran-3,4,5-triolio dariniai, skirti panaudoti diabeto gydymui |
KR101188333B1 (ko) | 2008-02-20 | 2012-10-09 | 에스케이케미칼주식회사 | 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염 |
US20090297591A1 (en) * | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
WO2009148613A1 (en) * | 2008-06-04 | 2009-12-10 | Coda Therapeutics, Inc. | Treatment of pain with gap junction modulation compounds |
US8366600B2 (en) * | 2008-06-19 | 2013-02-05 | Nupathe Inc. | Polyamine enhanced formulations for triptan compound iontophoresis |
US8155737B2 (en) | 2008-06-19 | 2012-04-10 | Nupathe, Inc. | Pharmacokinetics of iontophoretic sumatriptan administration |
CN102149280B (zh) | 2008-07-15 | 2017-05-24 | 泰拉科斯有限公司 | 氘化苄基苯衍生物及其使用方法 |
PT2324002T (pt) | 2008-08-22 | 2016-11-09 | Theracos Sub Llc | Processos para a preparação de inibidores de sglt2 |
WO2010068483A2 (en) | 2008-11-25 | 2010-06-17 | University Of Rochester | Mlk inhibitors and methods of use |
WO2010150100A1 (en) | 2009-06-24 | 2010-12-29 | Entarco Sa | The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer |
KR20110001103A (ko) * | 2009-06-29 | 2011-01-06 | 에스케이케미칼주식회사 | 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물 |
US20110003000A1 (en) * | 2009-07-06 | 2011-01-06 | Femmepharma Holding Company, Inc. | Transvaginal Delivery of Drugs |
EP2464234A4 (en) | 2009-08-10 | 2013-01-02 | Nupathe Inc | METHOD FOR IONTOPHORETIC TREATMENT OF IMMUNE AND MIGRAINE |
US20110087153A1 (en) * | 2009-10-13 | 2011-04-14 | Angelov Angel S | Transdermal Methods And Systems For The Delivery Of Rizatriptan |
IL210279A0 (en) | 2009-12-25 | 2011-03-31 | Dexcel Pharma Technologies Ltd | Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients |
KR101746204B1 (ko) | 2010-02-18 | 2017-06-13 | 에스케이케미칼주식회사 | 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물 |
KR20110094858A (ko) | 2010-02-18 | 2011-08-24 | 에스케이케미칼주식회사 | 피부 자극이 감소한 톨테로딘의 경피 투여용 조성물 |
WO2011136283A1 (ja) * | 2010-04-28 | 2011-11-03 | 久光製薬株式会社 | 皮膚刺激抑制剤及び経皮吸収製剤 |
WO2011149950A2 (en) | 2010-05-24 | 2011-12-01 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
US20130195957A1 (en) * | 2010-08-03 | 2013-08-01 | Hisamitsu Pharmaceutical Co., Inc. | Patch and method for enhancing adhesion force of the same |
EP2654757A1 (en) | 2010-12-22 | 2013-10-30 | Entarco SA | The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents |
WO2012112933A1 (en) | 2011-02-18 | 2012-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
US10195162B2 (en) | 2011-12-27 | 2019-02-05 | Teikoku Seiyaku Co., Ltd. | Tolterodine-containing adhesive patch |
CA2868534A1 (en) | 2012-03-27 | 2013-10-03 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
CN104768567B (zh) | 2012-05-18 | 2017-07-11 | 奥塔哥创业有限公司 | 用于伤口愈合的联合治疗和组合物 |
CN104114167B (zh) | 2012-06-12 | 2017-05-17 | Km特兰斯达股份有限公司 | 贴剂 |
WO2014051128A1 (ja) | 2012-09-28 | 2014-04-03 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
US10485800B2 (en) | 2012-11-30 | 2019-11-26 | The University Of Rochester | Mixed lineage kinase inhibitors for HIV/AIDS therapies |
CN103142465B (zh) * | 2013-03-19 | 2014-10-22 | 长春健欣生物医药科技开发有限公司 | 一种托特罗定成膜水凝胶制剂及其制备方法 |
WO2015143240A2 (en) | 2014-03-19 | 2015-09-24 | Curza Global, Llc | Compositions and methods comprising 2-(acylamino)imidazoles |
US9987361B1 (en) | 2014-12-29 | 2018-06-05 | Noven Pharmaceuticals, Inc. | Compositions and method for sustained drug delivery by active transdermal technology |
JP2020512981A (ja) | 2017-03-31 | 2020-04-30 | カーザ グローバル,リミティド ライアビリティ カンパニー | 置換2−アミノイミダゾールを含む組成物と方法 |
US11401339B2 (en) | 2018-08-23 | 2022-08-02 | Seagen Inc. | Anti-TIGIT antibodies |
US20230354981A1 (en) * | 2020-07-23 | 2023-11-09 | Kimberly-Clark Worldwide, Inc. | Method for modulating the bladder microbiome to improve bladder health |
AU2021376218A1 (en) | 2020-11-08 | 2023-06-15 | Seagen Inc. | Combination Therapy |
CN117730097A (zh) | 2021-04-09 | 2024-03-19 | 思进公司 | 以抗tigit抗体治疗癌症的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5382600A (en) | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
MX9302812A (es) * | 1992-05-13 | 1993-11-01 | Alza Corp | Administracion transdermica de oxibutinina. |
JP2000515525A (ja) | 1996-07-19 | 2000-11-21 | アベーグ,グンナー | 尿と胃腸の疾患の治療におけるs(―)―トルテロジン |
DK0877600T3 (da) * | 1996-08-09 | 2004-02-02 | Alcon Mfg Ltd | Konserveringssystem til farmaceutiske præparater indeholdende cyclodextrine |
SE9802864D0 (sv) * | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
-
1998
- 1998-08-27 SE SE9802864A patent/SE9802864D0/xx unknown
-
1999
- 1999-08-26 CA CA002341063A patent/CA2341063C/en not_active Expired - Fee Related
- 1999-08-26 EP EP99946522A patent/EP1105111B1/en not_active Expired - Lifetime
- 1999-08-26 JP JP2000567189A patent/JP2002523446A/ja active Pending
- 1999-08-26 NZ NZ509928A patent/NZ509928A/en unknown
- 1999-08-26 ES ES99946522T patent/ES2310942T3/es not_active Expired - Lifetime
- 1999-08-26 DE DE69939382T patent/DE69939382D1/de not_active Expired - Lifetime
- 1999-08-26 US US09/763,654 patent/US6517864B1/en not_active Expired - Fee Related
- 1999-08-26 AU AU58919/99A patent/AU758399B2/en not_active Ceased
- 1999-08-26 WO PCT/SE1999/001464 patent/WO2000012070A1/en active IP Right Grant
- 1999-08-26 AT AT99946522T patent/ATE405254T1/de not_active IP Right Cessation
- 1999-08-26 ES ES99946521T patent/ES2353765T3/es not_active Expired - Lifetime
- 1999-08-27 TW TW088114752A patent/TWI253349B/zh not_active IP Right Cessation
-
2000
- 2000-05-19 ZA ZA200002488A patent/ZA200002488B/xx unknown
-
2002
- 2002-11-22 US US10/301,719 patent/US7008637B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2000012070A1 (en) | 2000-03-09 |
CA2341063A1 (en) | 2000-03-09 |
SE9802864D0 (sv) | 1998-08-27 |
ATE405254T1 (de) | 2008-09-15 |
US20030124179A1 (en) | 2003-07-03 |
CA2341063C (en) | 2008-02-12 |
EP1105111A1 (en) | 2001-06-13 |
AU758399B2 (en) | 2003-03-20 |
NZ509928A (en) | 2003-08-29 |
US7008637B2 (en) | 2006-03-07 |
AU5891999A (en) | 2000-03-21 |
TWI253349B (en) | 2006-04-21 |
US6517864B1 (en) | 2003-02-11 |
JP2002523446A (ja) | 2002-07-30 |
DE69939382D1 (de) | 2008-10-02 |
ES2353765T3 (es) | 2011-03-04 |
ES2310942T3 (es) | 2009-01-16 |
EP1105111B1 (en) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200002488B (en) | Therapeutic formulation for administering tolterodine with controlled release. | |
ATE370737T1 (de) | Verwendung oraler formulierungen zur behandlung der weiblichen sexuellen störung | |
HUP0204229A2 (hu) | Orális opioid készítmények, eljárás az előállításukra és alkalmazásuk | |
MXPA05004381A (es) | Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos. | |
NO980700D0 (no) | Perifert aktive anti-hyperalgesi opiater | |
HUP0100437A2 (hu) | Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására | |
TR200201317T2 (tr) | Sinerjistik kombinasyon. | |
SE9803986D0 (sv) | New compositions | |
CA2316349A1 (en) | Compositions and method for protecting skin from uv induced immunosuppression and skin damage | |
ATE323473T1 (de) | Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon | |
IS2803B (is) | Fentanýlsamsetning fyrir gjöf í nef | |
WO2003068171A3 (en) | Method and composition for treatment of inflammation and aids-associated neurological disorders | |
EP0200490A3 (en) | Compositions for noninvasive administration of sedatives, analgesics, and anesthetics | |
IS4553A (is) | Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara | |
HUP0300833A2 (hu) | Gabapentin analogonok alvászavarok kezelésére | |
CA2401000A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
NZ332215A (en) | Transdermally administered dextromethorphan as antitussive agent | |
NZ590981A (en) | Transdermal therapeutic system (TTS) for administration with a wafer | |
BR0005797A (pt) | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados | |
NO20013414L (no) | Ny anvendelse av melagatran | |
BR0315482A (pt) | Composições farmacêuticas e formas de dosagem para liberações bucal e sublingual da tizanidina e métodos de administração da tizanidina de forma sublingual ou bucal | |
SE0004101D0 (sv) | New use | |
IS2576B (is) | Samverkandi samsetning sem felur í sér róflúmílast og (R.R)-formóteról | |
HUP0402326A2 (hu) | Gyógyszerkészítmény addikció megelőzésére fájdalom kezelésében | |
CA2077693A1 (en) | Use of ketorolac for treatment of periodontal disease |